Most notably, alterations of STK11/LKB1 in the presence of KRAS mutations have been linked to primary resistance to PD-1 inhibitors in lung adenocarcinoma patients undergoing chemoimmunotherapy (8). The gene discussed is STK11; the disease is lung adenocarcinoma.